Reaction

Cytomegalovirus Enterocolitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 752 reports · 41 co-occurring drugs

As of the last recalculation, Cytomegalovirus Enterocolitis appears in 752 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is GANCICLOVIR SODIUM (PRR 149.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ganciclovir Sodium	53	149.1	149.8
Ganciclovir	51	147.9	148.6
Bendamustine Hydrochloride	44	107.9	108.3
Polatuzumab Vedotin	21	61.2	61.4
Micafungin Sodium	17	56.8	56.9
Anti-Thymocyte Globulin (Rabbit)	16	56.1	56.2
Basiliximab	19	45.8	45.9
Valganciclovir	30	45.8	45.9
Valganciclovir Hydrochloride	30	45.8	45.9
Cefepime	20	39.6	39.7
Cefepime Hydrochloride	21	37.1	37.1
Valganciclovir Hydrochloride Powder,	16	37.1	37.1
Obinutuzumab	21	36.3	36.4
Amphotericin B	14	31.5	31.5
Prednisolone	148	28.0	28.0
Prednisolone Oral	148	28.0	28.0
Prednisolone Oral Solution	148	28.0	28.0
Tacrolimus	129	27.3	27.3
Posaconazole Delayed-Release	10	25.5	25.6
Voriconazole	26	24.5	24.5
Remdesivir	11	23.2	23.2
Ipilimumab	34	22.8	22.8
Voriconazole Injection	16	20.8	20.8
Mesalamine	38	19.7	19.7
Tacrolimus Ointment 0.1%	79	19.5	19.5
Tacrolimus Extended-Release Capsules	79	19.4	19.5
Febuxostat Tablets 40 Mg	7	19.2	19.2
Febuxostat Tablets 80 Mg	7	19.2	19.2
Melphalan Hydrochloride	17	19.2	19.2
Posaconazole	11	19.0	19.0
Melphalan	15	18.6	18.6
Busulfan	10	17.8	17.8
Vancomycin Hydrochloride	39	17.2	17.2
Nivolumab	55	16.9	16.9
Meropenem	18	15.9	15.9
Dasatinib	18	13.7	13.7
Daratumumab	18	12.8	12.8
Blinatumomab	4	10.7	10.7
Durvalumab	7	9.6	9.6
Atezolizumab	13	9.4	9.4
Axicabtagene Ciloleucel	3	8.4	8.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.